Prestige Biopharma IDC Publishes Non-Clinical Efficacy of CRS Therapeutic Candidate in International Journal

The results of a preclinical efficacy evaluation of 'IDC007', a candidate treatment for cytokine release syndrome (CRS) currently being developed by Prestige Biopharma IDC, have been published in the international academic journal 'Frontiers in Immunology'.

According to Prestige Biopharma on July 16, IDC007, as introduced in the journal, is a bispecific antibody designed to simultaneously target 'TNF-α'—involved in the initial inflammatory response—and the 'IL-6 receptor (IL-6R)', which amplifies systemic inflammation. This dual action is intended to overcome the limitations of existing therapies that block only a single signal, and to suppress the onset and progression of CRS from multiple angles.

The research team demonstrated through cell-based and animal model experiments that IDC007 not only suppresses CRS-inducing immune responses but also effectively prevents organ and vascular damage. Notably, in humanized CRS mouse models treated two hours after symptom induction—rather than as a preventative measure—IDC007 achieved a 100% survival rate, highlighting its potential as an actual therapeutic intervention.

Nari Kim, Head of the Precision Antibody Group at Prestige Biopharma IDC, stated, "This study demonstrates that the multi-target blocking mechanism of IDC007 is effective in managing severe CRS," adding, "Based on the successful therapeutic administration after symptom onset, we will accelerate its development as an innovative new drug going forward."

This content was produced with the assistance of AI translation services.